D.A. Davidson & CO. Sells 46 Shares of Cencora, Inc. (NYSE:COR)

D.A. Davidson & CO. decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,846 shares of the company’s stock after selling 46 shares during the quarter. D.A. Davidson & CO.’s holdings in Cencora were worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Citizens & Northern Corp grew its stake in shares of Cencora by 3.0% during the fourth quarter. Citizens & Northern Corp now owns 7,354 shares of the company’s stock valued at $1,652,000 after buying an additional 212 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Cencora by 3.3% in the fourth quarter. CIBC Asset Management Inc now owns 40,542 shares of the company’s stock valued at $9,101,000 after purchasing an additional 1,305 shares during the period. AlphaCentric Advisors LLC purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $221,000. Principal Financial Group Inc. boosted its holdings in shares of Cencora by 3.8% in the fourth quarter. Principal Financial Group Inc. now owns 318,401 shares of the company’s stock valued at $71,538,000 after purchasing an additional 11,675 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $63,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $250.59 on Wednesday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The stock has a fifty day moving average price of $240.27 and a 200-day moving average price of $237.56. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $48.60 billion, a PE ratio of 35.65, a P/E/G ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. Cencora’s dividend payout ratio is presently 31.29%.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird boosted their price target on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company upped their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.